Health Concerns

Kidney Health


Abdel-Zaher AO, Abdel-Hady RH, Mahmoud MM, Farrag MM. The potential protective role of alpha-lipoic acid against acetaminophen-induced hepatic and renal damage. Toxicology. 2008 Jan 20;243(3):261-70.

Ahmed N, Thornalley PJ. Advanced glycation endproducts: what is their relevance to diabetic complications? Diabetes Obes Metab. 2007 May;9(3):233-45.

Alderson NL, Chachich ME, Frizzell N, et al. Effect of antioxidants and ACE inhibition on chemical modification of proteins and progression of nephropathy in the streptozotocin diabetic rat. Diabetologia. 2004 Aug;47(8):1385-95.

Amudha G, Josephine A, Mythili Y, Sundarapandiyan R, Varalakshmi P. Therapeutic efficacy of DL-alpha-lipoic acid on cyclosporine A induced renal alterations. Eur J Pharmacol. 2007a Oct 1;571(2-3):209-14.

Amudha G, Josephine A, Varalakshmi P. Beneficial effect of DL-alpha-lipoic acid on cyclosporine A induced hyperlipidemic nephropathy in rats. Mol Cell Biochem. 2007b Jul;301(1-2):165-71.

Amudha G, Josephine A, Varalakshmi P. Role of lipoic acid in reducing the oxidative stress induced by cyclosporine A. Clin Chim Acta. Oct 2006;372(1-2):134-9.

Andreotti, F., Burzotta, F., Mazza, A., Manzoli, A., Robinson, K., Maseri, A. Homocysteine and arterial occlusive disease: a concise review. Cardiologia 1999 Apr; 44(4): 341-5.

Aukema, H.M., Housini, I., Rawling, J.M. Dietary soy protein effects on inherited polycystic kidney disease are influenced by gender and protein level. J. Am. Soc. Nephrol. 1999 Feb; 10(2): 300-8.

Bacallao, R.L., Carone, F.A. Recent advances in the understanding of polycystic kidney disease. Curr. Opin. Nephrol. Hypertens. 1997 Jul; 6(4): 377-83.

Barak, A.J., Beckenhauer, H.C., Tuma, D.J. Betaine, ethanol, and the liver: a review. Alcohol 1996; 13: 395-8.

Bertelli AA, Migliori M, Panichi V, et al. Resveratrol, a component of wine and grapes, in the prevention of kidney disease. Ann N Y Acad Sci. 2002 May;957:230-8.

Bhatti F, Mankhey RW, Asico L, Quinn MT, Welch WJ, Maric C. Mechanisms of antioxidant and pro-oxidant effects of alpha-lipoic acid in the diabetic and nondiabetic kidney. Kidney Int. 2005 Apr;67(4):1371-80.

Bokemeyer C, Fels LM, Dunn T, et al. Silibinin protects against cisplatin-induced nephrotoxicity without compromising cisplatin or ifosfamide anti-tumour activity. Br J Cancer. 1996 Dec;74(12):2036-41.

Boldt, J., Brosch, C., Piper, S.N., Suttner, S. et al. Influence of prophylactic use of pentoxifylline on postoperative organ function in elderly cardiac surgery patients. Crit. Care Med. 2001 May; 29(5): 952?8.

Bostom, A.G., Shemin, D., Lapane, K.L., Hume, A.L., Yoburn, D., Nadeau, M.R., Bendich, A., Selhub, J., Rosenberg, I.H. High-dose B-vitamin treatment of hyperhomocysteinemia in dialysis patients. Kidney Int. 1996 Jan; 49(1): 147-52.

Brkljacic, B. et al. Renal vascular resistance in autosomal dominant polycystic kidney disease. Evaluation with color Doppler ultrasound. Acta Radiol. 1997 Sep; 38(5): 840-6.

Caimi G, Carollo C, Lo Presti R. Chronic renal failure: oxidative stress, endothelial dysfunction and wine. Clin Nephrol. 2004 Nov;62(5):331-5.

Chambers, S.T. Betaines: their significance for bacteria and the renal tract. Clin. Sci. 1995; 88(1): 25-7.

Chander V, Chopra K. Protective effect of nitric oxide pathway in resveratrol renal ischemia-reperfusion injury in rats. Arch Med Res. Jan 2006a;37(1):19-26.

Chander V, Chopra K. Protective effect of resveratrol, a polyphenolic phytoalexin on glycerol-induced acute renal failure in rat kidney. Ren Fail. 2006b;28(2):161-9.

Chander V, Chopra K. Role of nitric oxide in resveratrol-induced renal protective effects of ischemic preconditioning. J Vasc Surg. 2005a Dec;42(6):1198-205.

Chander V, Tirkey N, Chopra K. Resveratrol, a polyphenolic phytoalexin protects against cyclosporine-induced nephrotoxicity through nitric oxide dependent mechanism. Toxicology. 2005b May 15;210(1):55-64.

Chapman, A.B., Johnson, A.M., Rainguet, S., Hossack, K., Gabow, P., Schrier, R.W. Left ventricular hypertrophy in autosomal dominant polycystic kidney disease. J. Am. Soc. Nephrol. 1997 Aug; 8(8): 1292-7.

Chauveau P, Chadefaux B, Coudé M, et al. Hyperhomocysteinemia, a risk factor for atherosclerosis in chronic uremic patients. Kidney Int Suppl. 1993;41:S72-7.

Chauveau, P., Chadefaux, B., Coude, M., Aupetit, J., Kamoun, P., Jungers, P. Long-term folic acid (but not pyridoxine) supplementation lowers elevated plasma homocysteine level in chronic renal failure. Miner. Electrolyte Metab. 1996; 22(1-3): 106-9.

Clarke, R., Daly, L., Robinson, K., Naughten, E., Cahalane, S., Fowler, B., Graham, I. Hyperhomocysteinemia: an independent risk factor for vascular disease. N. Engl. J. Med. 1991 Apr 25; 324(17): 1149-55.

Clermont, G., Lecour, S., Lahet, J., Siohan, P., Vergely, C., Chevet, D., Rifle, G., Rochette, L. Alteration in plasma antioxidant capacities in chronic renal failure and hemodialysis patients: a possible explanation for the increased cardiovascular risk in these patients. Cardiovasc. Res. 2000 Aug 18; 47(3): 618-23.

Dierkes, J. et al. Response of hyperhomocysteinemia to folic acid supplementation in patients with end-stage renal disease. Clin. Nephrol. 1999 Feb; 51(2): 108-15.

Dlugosz A, Kuzniar J, Sawicka E, et al. Oxidative stress and coenzyme Q10 supplementation in renal transplant recipients. Int Urol Nephrol. 2004;36(2):253-8.

Do Amaral CL, Francescato HD, Coimbra TM, et al. Resveratrol attenuates cisplatin-induced nephrotoxicity in rats. Arch Toxicol. 2008 Jun;82(6):363-70.

El-Shitany NA, El-Haggar S, El-desoky K. Silymarin prevents adriamycin-induced cardiotoxicity and nephrotoxicity in rats. Food Chem Toxicol. 2008 Jul;46(7):2422-8.

Ettinger, B. et al. Potassium-magnesium citrate is an effective prophylaxis against recurrent calcium oxalate nephrolithiasis. J. Urol. 1997 Dec; 158(6): 2069-73.

Farswan M, Rathod SP, Upaganlawar AB, Semwal A. Protective effect of coenzyme Q10 in simvastatin and gemfibrozil induced rhabdomyolysis in rats. Indian J Exp Biol. 2005 Oct 2005;43(10):845-8.

Floersheim GL. Experimental basis for the therapy of Amanita phalloides poisoning. Schweiz Med Wochenschr. 1978 Feb 11;108(6):185-97.

Fored, C.M., Ejerblad, E., Lindblad, P., Fryzek, J.P., Dickman, P.W., Signorello, L.B., Lipworth, L., Elinder, C.G., Blot, W.J., McLaughlin, J.K., Zack, M.M., Nyren, O. Acetaminophen, aspirin, and chronic renal failure. N. Engl. J. Med. 2001 Dec 20; 345(25): 1801-8; comment, N. Engl. J. Med. 2001 Dec 20; 345(25): 1844-6.

Franconi, F., Bennardini, F., Mattana, A. et al. Plasma and platelet taurine are reduced in subjects with insulin-dependent diabetes mellitus: effects of taurine supplementation. Am. J. Clin. Nutr. 1995; 61: 1115-9.

Friedman, A.N., Bostom, A.G., Selhub, J., Levey, A.S., Rosenberg, I.H. The kidney and homocysteine metabolism. J. Am. Soc. Nephrol. 2001 Oct; 12(10): 2181-9.

Fukaya, H., Kanno, H. Experimental studies of the protective effect of ginkgo biloba extract (GBE) on cisplatin-induced toxicity in rats. Nippon Jibinkoka Gakkai Kaiho 1999 Jul; 102(7): 907-17 (in Japanese).

Gaedeke J, Fels LM, Bokemeyer C, Mengs U, Stolte H, Lentzen H. Cisplatin nephrotoxicity and protection by silibinin. Nephrol Dial Transplant. 1996 Jan;11(1):55-62.

Gahl, W.A., Bernardini, I., Chen, S., Kurtz, D., Horvath, K. The effect of oral betaine on vertebral body bone density in pyridoxine-non-responsive homocystinuria. J. Inherit. Metab. Dis. 1988; 11: 291-8.

Gazdikova K, Gvozdjakova A, Kucharska J, Spustova V, Braunova Z, Dzurik R. Malondialdehyde and selected antioxidant plasma levels in conservatively treated patients with kidney diseases. Bratisl Lek Listy. 2000;101(9):490-4.

Giovannini L, Migliori M, Longoni BM, et al. Resveratrol, a polyphenol found in wine, reduces ischemia reperfusion injury in rat kidneys. J Cardiovasc Pharmacol. 2001 Mar;37(3):262-70.

Glanze, W.D. The Mosby Medical Encyclopedia, Revised Edition 1996. St. Louis, MO: C.V. Mosby.

Grantham, J.J. Mechanisms of progression in autosomal dominant polycystic kidney disease. Kidney Int. Suppl. 1997 Dec; 63: S93-S97.

Grantham, J.J., Nair, V., Winklhofer, F. Cystic disease of the kidney. In Brenner & Rector's The Kidney, Volume 2, Sixth Edition 2000, pp. 1699-1730. Philadelphia, PA: W.B. Saunders.

Hahn, S. et al. Glomerulosclerosis in the remnant kidney rat is modulated by dietary alpha-tocopherol. J. Am. Soc. Nephrol. 1998 Nov; 9(11): 2089-95.

Herrmann, W., Schorr, H., Geisel, J., Riegel, W. Homocysteine, cystathionine, methylmalonic acid and B-vitamins in patients with renal disease. Clin. Chem. Lab. Med. 2001 Aug; 39(8): 739-46.

Hoffer, L.J., Robitaille, L., Elian, K.M., Bank, I., Hongsprabhas, P., Mamer, O.A. Plasma reduced homocysteine concentrations are increased in end-stage renal disease. Kidney Int. 2001 Jan; 59(1): 372-7.

Igarashi T, Nakajima Y, Tanaka M, Otake S. Effect of coenzyme Q10 on experimental hypertension in rats and dogs. J Pharmacol Exp Ther. 1974 Apr;189(1):149-56.

Joosten, E., Lesaffre, E., Riezler, R., Ghekiere, V., Dereymaeker, L., Pelemans, W., Dejaeger, E. Is metabolic evidence for vitamin B-12 and folate deficiency more frequent in elderly patients with Alzheimer's disease? J. Gerontol. A Biol. Sci. Med. Sci. 1997 Mar; 52(2): M76-M79.

Kalinowski, M. et al. Effects of L-carnitine on erythropoiesis and blood platelet aggregation in patients with chronic renal failure treated with hemodialysis. Pol. Merkuriusz. Lek. 1999 Feb; 6(32): 76-8.

Karimi G, Ramezani M, Tahoonian Z. Cisplatin nephrotoxicity and protection by milk thistle extract in rats. Evid Based Complement Alternat Med. 2005 Sep;2(3):383-6.

Kirsten R, Heintz B, Nelson K, et al. Magnesium pyridoxal 5-phosphate glutamate reduces hyperlipidaemia in patients with chronic renal insufficiency. Eur J Clin Pharmacol. 1988;34(2):133-7.

Kolgazi M, Sener G, Cetinel S, Gedik N, Alican I. Resveratrol reduces renal and lung injury caused by sepsis in rats. J Surg Res. 2006 Aug;134(2):315-21.

LaPorte, J. et al. Kidney stones. How to identify the cause and prevent recurrence. Postgrad. Med. 1990 Apr; 87(5): 219-23, 226.

Launay-Vacher V, Rey JB, Isnard-Bagnis C, Deray G, Daouphars M, European Society of Clinical Pharmacy Special Interest Group on Cancer C. Prevention of cisplatin nephrotoxicity: state of the art and recommendations from the European Society of Clinical Pharmacy Special Interest Group on Cancer Care. Cancer Chemother Pharmacol. 2008 May;61(6):903-9.

Levin, A., Stevens, L., McCullough, P.A. Cardiovascular disease and the kidney: tracking a killer in chronic kidney disease. Postgrad. Med. 2002; 111(4): 53-60.

Li Kam Wa, T.C. Ambulatory blood pressure in hypertensive patients with autosomal dominant polycystic kidney disease. Nephrol. Dial. Transplant. 1997 Oct; 12(10): 2075-80.

Licinio, J., Wong, M.L. The role of inflammatory mediators in the biology of major depression: central nervous system cytokines modulate the biological substrate of depressive symptoms, regulate stress-responsive systems, and contribute to neurotoxicity and neuroprotection. Mol. Psychiatry 1999 Jul; 4(4): 317?27.

Lingens, N., Freund, M., Seeman, T., Witte, K., Lemmer, B., Scharer, K. Circadian blood pressure changes in untreated children with kidney disease and conserved renal function. Acta Paediatr. 1997 Jul; 86(7): 719-23.

Lippa S, Colacicco L, Bondanini F, et al. Plasma levels of coenzyme Q(10), vitamin E and lipids in uremic patients on conservative therapy and hemodialysis treatment: some possible biochemical and clinical implications. Clin Chim Acta. 2000 Feb 25;292(1-2):81-91.

Machado V, Cabral A, Monteiro P, Goncalves L, Providencia LA. Carvedilol as a protector against the cardiotoxicity induced by anthracyclines (doxorubicin). Rev Port Cardiol. 2008 Oct;27(10):1277-96.

Malarkodi KP, Balachandar AV, Varalakshmi P. Protective effect of lipoic acid on adriamycin induced lipid peroxidation in rat kidney. Mol Cell Biochem. 2003a May;247(1-2):9-13.

Malarkodi KP, Balachandar AV, Varlakshmi P. The influence of lipoic acid on adriamycin-induced hyperlipidemic nephrotoxicity in rats. Mol Cell Biochem. 2003b May;247(1-2):139-45.

Marangon, K., O'Byrne, D., Devaraj, S., Jialal, I. Validation of an immunoassay for measurement of plasma total homocysteine. Am. J. Clin. Pathol. 1999 Dec; 112(6): 757-62.

McCaddon, A., Davies, G., Hudson, P., Tandy, S., Cattell, H. Total serum homocysteine in senile dementia of Alzheimer type. Int. J. Geriatr. Psychiatry 1998 Apr; 13(4): 235-9.

McCully, KS. Vascular pathology of homocysteinemia: implications for the pathogenesis of arteriosclerosis. Am. J. Pathol. 1969 Jul; 56(1): 111-28.

McGregor, D., Shand, B., Lynn, K. A controlled trial of the effect of folate supplements on homocysteine, lipids and hemorheology in end-stage renal disease. Nephron 2000 Jul; 85(3): 215-20.

Merta, M., Stekrova, J., Zidovska, J., Vorsilkova, M., Walterova, J., Kapras, J., Alanova, M., Raskova, D., Gaillyova, R., Archmanova, E., Rysava, R. DNA diagnosis and clinical manifestations of autosomal dominant polycystic kidney disease. Folia Biol. 1997; 43(5): 201-4.

Metz TO, Alderson NL, Chachich ME, Thorpe SR, Baynes JW. Pyridoxamine traps intermediates in lipid peroxidation reactions in vivo: evidence on the role of lipids in chemical modification of protein and development of diabetic complications. J Biol Chem. 2003a Oct 24;278(43):42012-9.

Metz TO, Alderson NL, Thorpe SR, Baynes JW. Pyridoxamine, an inhibitor of advanced glycation and lipoxidation reactions: a novel therapy for treatment of diabetic complications. Arch Biochem Biophys. 2003b Nov 1;419(1):41-9.

Miller-Hjelle, M.A. et al. Polycystic kidney disease: an unrecognized emerging infectious disease? Emerg. Infect. Dis. 1997 Apr-Jun; 3(2): 113-27.

Miller-Hjelle, M.A. et al. Polycystic kidney disease: an unrecognized emerging infectious disease? Emerg. Infect. Dis. 1997 Apr-Jun;3(2): 113-27.

Morotomi Y, Oniki H, Onoyama K, Fukiyama K, Omae T. Effects of coenzyme Q10 on the blood pressure and renal renin content in spontaneously hypertensive rats. Igaku Kenkyu. 1975 Nov;45(5):303-8.

Mukoyama, A., Ushijima, H., Nishimura, S., Koike, H., Toda, M., Hara, Y., Shimamura, T. Inhibition of rotavirus and enterovirus infections by tea extracts. Jpn. J. Med. Sci. Biol. 1991 Aug; 44(4): 181-6.

Naidu, M.U., Shifow, A.A., Kumar, K.V., Ratnaker, K.S. Ginkgo biloba extract ameliorates gentamicin-induced nephrotoxicity in rats. Phytomedicine 2000 Jun; 7(3): 191-7.

Nakamura S, Li H, Adijiang A, Pischetsrieder M, Niwa T. Pyridoxal phosphate prevents progression of diabetic nephropathy. Nephrol Dial Transplant. 2007 Aug;22(8):2165-74.

National Kidney and Urologic Diseases Information Clearinghouse (NKUDIC). What Are Kidney Stones? 1998. Bethesda, MD: National Kidney and Urologic Diseases Information Clearinghouse/ National Institute of Diabetes & Digestive & Kidney Diseases.

National Kidney Foundation. Millions of Americans May Be at Risk for Kidney Disease: Simple Blood Tests Can Detect Your Risk 2001a Feb 26. New York: National Kidney Foundation (

National Kidney Foundation. Phosphorous and Renal Diet 2001c. New York: National Kidney Foundation.

National Kidney Foundation. Potassium and Renal Diet 2001d. New York: National Kidney Foundation.

National Kidney Foundation. Vitamins and Minerals in Kidney Disease 2001e. New York: National Kidney Foundation.

Navarro, J.F., Mora, C., Garcia, J. et al. Effects of pentoxifylline on the haematologic status in anaemic patients with advanced renal failure. Scand. J. Urol. Nephrol. 1999b Apr; 33(2): 121?5.

Navarro, J.F., Mora, C., Rivero, A., et al. Urinary protein excretion and serum tumor necrosis factor in diabetic patients with advanced renal failure: effects of pentoxifylline administration. Am. J. Kidney Dis. 1999a Mar; 33(3): 458?63.

NCHS. Current Estimates from the National Health Interview Survey, 1996. 1999 Oct, Series 10(200). Atlanta, GA: National Center for Health Statistics/Centers for Disease Control and Prevention/U.S. Department of Health and Human Services.

NIDDK. Anemia in Kidney Disease and Dialysis 2001 Apr. Bethesda, MD: National Institute of Diabetes & Digestive & Kidney Diseases/National Institutes of Health (

NIDDK. Anemia in Kidney Disease and Dialysis 2001a Apr. Bethesda, MD: National Institute of Diabetes & Digestive & Kidney Diseases/National Institutes of Health (

NIDDK. Kidney and Urologic Diseases Statistics for the United States 2001b Dec. Bethesda, MD: National Institute of Diabetes & Digestive & Kidney Diseases/National Institutes of Health (

NIDDK. Kidney Diseases Dictionary Index 1999. Bethesda, MD: National Institute of Diabetes & Digestive & Kidney Diseases/National Institutes of Health (

NIDDK. What Are Kidney Stones? 1998. Bethesda, MD: National Institute of Diabetes & Digestive & Kidney Diseases/National Institutes of Health (

NKF. National Kidney Foundation. Nutritional and Chronic Kidney Disease. 2002. Available at: Accessed October 9, 2012.

NORD. Renal Disease Overview 2002. Universal City, CA: National Organization for Renal Disease (

Ogborn, M.R., Nitschmann, E., Weiler, H.A., Bankovic-Calic, N. Modification of polycystic kidney disease and fatty acid status by soy protein diet. Kidney Int. 2000 Jan; 57(1): 159-66.

Ohgitani, S., Fujita, T. Calcium decreases urinary oxalate. Nippon Ronen Igakkai Zasshi 2000 Oct; 37(10): 805-10 (in Japanese).

Post-White J, Ladas EJ, Kelly KM. Advances in the use of milk thistle (Silybum marianum). Integr Cancer Ther. 2007 Jun;6(2):104-9.

Ranich, T., Bhathena, S.J., Velasquez, M.T. Protective effects of dietary phytoestrogens in chronic renal disease. J. Ren. Nutr. 2001 Oct; 11(4): 183-93.

Robinson, K., Gupta, A., Dennis, V., Arheart, K., Chaudhary, D., Green, R., Vigo, P., Mayer, E.L., Selhub, J., Kutner, M., Jacobsen, D.W. Hyperhomocysteinemia confers an independent increased risk of atherosclerosis in end-stage renal disease and is closely linked to plasma folate and pyridoxine concentrations. Circulation 1996 Dec 1; 94(11): 2743-8.

Rodgers, A.L. et al. Effect of mineral water containing calcium and magnesium on calcium oxalate urolithiasis risk factors. Urol. Int. 1997;58(2): 93-9.

Rodgers, A.L. et al. Effect of mineral water containing calcium and magnesium on calcium oxalate urolithiasis risk factors. Urol. Int. 1997;58(2): 93-9.

Sadava, D., Luo, P.W., Casper, J. Induction of renal damage in rats by a diet deficient in antioxidants. Nutr. Res. 1996; 16(9): 1607-12.

Saionji, K. et al. Homeostasis of antioxidant status in hemodialysis patients. Rinsho Byori 1999 May; 47(5): 461-6 (in Japanese).

Saito M, Satoh S, Kojima N, et al. Effects of a phenolic compound, resveratrol, on the renal function and costimulatory adhesion molecule CD86 expression in rat kidneys with ischemia/reperfusion injury. Arch Histol Cytol. 2005;68(1):41-9.

Sakurauchi, Y. et al. Effects of L-carnitine supplementation on muscular symptoms in hemodialyzed patients. Am. J. Kidney Dis. 1998 Aug; 32(2): 258-64.

Sehirli O, Sener E, Cetinel S, Yuksel M, Gedik N, Sener G. Alpha-lipoic acid protects against renal ischaemia-reperfusion injury in rats. Clin Exp Pharmacol Physiol. 2008 Mar ;35(3):249-55.

Selhub, J. Homocysteine metabolism. Annu. Rev. Nutr. 1999; 19: 217-46.

Selhub, J., Jacques, P.F., Bostom, A.G., D'Agostino, R.B., Wilson, P.W., Belanger, A.J., O'Leary, D.H., Wolf, P.A., Schaefer, E.J., Rosenberg, I.H. Association between plasma homocysteine concentrations and extracranial carotid-artery stenosis. N. Engl. J. Med. 1995 Feb 2; 332(5): 286-91.

Seshadri, S., Beiser, A., Selhub, J., Jacques, P.F., Rosenberg, I.H., D'Agostino, R.B., Wilson, P.W., Wolf, P.A. Plasma homocysteine as a risk factor for dementia and Alzheimer's disease. N. Engl. J. Med. 2002 Feb 14; 346(7): 476-83.

Sessa, A., Ghiggeri, G.M., Turco A.E. Autosomal dominant polycystic kidney disease: clinical and genetic aspects. J. Nephrol. 1997 Nov-Dec; 10(6): 295-310.

Sharma S, Anjaneyulu M, Kulkarni SK, Chopra K. Resveratrol, a polyphenolic phytoalexin, attenuates diabetic nephropathy in rats. Pharmacology. 2006;76(2):69-75.

Silan C, Uzun O, Comunoglu NU, Gokcen S, Bedirhan S, Cengiz M. Gentamicin-induced nephrotoxicity in rats ameliorated and healing effects of resveratrol. Biol Pharm Bull. 2007 Jan;30(1):79-83.

Sloan, R.S., Kastan, B., Rice, S.I., Sallee, C.W., Yuenger, N.J., Smith, B., Ward, R.A., Brier, M.E., Golper, T.A. Quality of life during and between hemodialysis treatments: role of L-carnitine supplementation. Am. J. Kidney Dis. 1998 Aug; 32(2): 265-72; comment, Am. J. Kidney Dis. 1999 Aug; 34(2): 400-1.

Stampfer, M.J., Malinow, M.R. Can lowering homocysteine levels reduce cardiovascular risk? N. Engl. J. Med. 1995 Feb 2; 332(5): 328-9.

Stampfer, M.J., Malinow, M.R., Willett, W.C., Newcomer, L.M., Upson, B., Ullmann, D., Tishler, P.V., Hennekens, C.H. A prospective study of plasma homocyst(e)ine and risk of myocardial infarction in U.S. physicians. JAMA 1992 Aug 19; 268(7): 877-81.

Suliman, M.E., Lindholm, B., Barany, P., Bergstrom, J. Hyperhomocysteinemia in chronic renal failure patients: relation to nutritional status and cardiovascular disease. Clin. Chem. Lab. Med. 2001 Aug; 39(8): 734-8.

Suresh Babu, P., Srinivasan, K. Amelioration of renal lesions associated with diabetes by dietary curcumin in streptozotocin diabetic rats. Mol. Cell. Biochem. 1998 Apr; 181(1-2): 87-96.

Takaoka M, Ohkita M, Kobayashi Y, Yuba M, Matsumura Y. Protective effect of alpha-lipoic acid against ischaemic acute renal failure in rats. Clin Exp Pharmacol Physiol. 2002 Mar;29(3):189-94.

Takei, K., Ito, H., Masai, M., Kotake, T. Oral calcium supplement decreases urinary oxalate excretion in patients with enteric hyperoxaluria. Urol. Int. 1998; 61(3): 192-5.

Tomobe, K., Philbrick, D.J., Ogborn, M.R., Takahashi, H., Holub, B.J. Effect of dietary soy protein and genistein on disease progression in mice with polycystic kidney disease. Am. J. Kidney Dis. 1998 Jan; 31(1): 55-61.

Trachtman, H., Sturman, J.A. Taurine: a therapeutic agent in experimental kidney disease. Amino Acids 1996; 11(1): 1-13.

Tucker, K.L., Mahnken, B., Wilson, P.W., Jacques, P., Selhub, J. Folic acid fortification of the food supply. Potential benefits and risks for the elderly population. JAMA 1996 Dec 18; 276(23): 1879-85.

Ueland, P.M., Ulvik, R.J., Refsum, H. Routine determination of homocysteine in plasma. A new and improved possibility for risk evaluation and diagnosis of common diseases. Tidsskr. Nor. Laegenforen. 1992 Sep 30; 112(23): 2977-80 (in Norwegian).

Umegaki, K., Shinozuka, K., Watarai, K., Takenaka, H., Yoshimura, M., Daohua, P., Esashi, T. Gingo biloba extract attenuates the development of hypertension in dioxycorticosterone acetate-salt hypertensive rats. Clin. Exp. Pharmacol. Physiol. 2000 Apr; 27(4): 277-82.

University of New Hampshire (UNH) Health Services. The Body Art Project: The Urinary System. Available at: Last updated 2012. Accessed October 1, 2012.

Upaganlawar A, Farswan M, Rathod S, Balaraman R. Modification of biochemical parameters of gentamicin nephrotoxicity by coenzyme Q10 and green tea in rats. Indian J Exp Biol. 2006 May;44(5):416-8.

USRDS. USRDS 2001 Annual Data Report 2001 Nov 21. U.S. Renal Data System. Bethesda, MD: National Institute of Diabetes and Digestive and Kidney Diseases/National Institutes of Health (

USRDS. USRDS 2012 Annual Data Report. ESRD Payment Policy Changes: The New “Bundled” Dialysis Prospective Payment System (PPS) in the United States. Available at: Accessed October 9, 2012.

Van der Meide, P.H., Schellekens, H. Cytokines and the immune response. Biotherapy 1996; 8(3-4): 243?9.

van Guldener, C., Janssen, M.J., de Meer, K. et al. Effect of folic acid and betaine on fasting and postmethionine-loading plasma homocysteine and methionine levels in chronic haemodialysis patients. J. Intern. Med. 1999; 245: 175-83.

van Guldener, C., Stehouwer, CD. Hyperhomocysteinemia, vascular pathology, and endothelial dysfunction. Semin. Thromb. Hemost. 2000; 26(3): 281?9.

Velasquez, M.T., Bhathena, S.J. Dietary phytoestrogens: a possible role in renal disease protection. Am. J. Kidney Dis. 2001 May; 37(5): 1056-68.

Venkatesan, N., Punithavathi, D., Arumugam, V. Curcumin prevents adriamycin nephrotoxicity in rats. Br. J. Pharmacol. 2000 Jan; 129(2): 231-4.

Verhoef, P., Stampfer, M.J., Buring, J.E., Gaziano, J.M., Allen, R.H., Stabler, S.P., Reynolds, R.D., Kok, F.J., Hennekens, C.H., Willett, W.C. Homocysteine metabolism and risk of myocardial infarction: relation with vitamins B6, B12, and folate. Am. J. Epidemiol. 1996 May 1; 143(9): 845-59.

Vogel G, Braatz R, Mengs U. On the nephrotoxicity of alpha-amanitin and the antagonistic effects of silymarin in rats. Agents Actions. 1979 Jun;9(2):221-6.

Voziyan PA, Hudson BG. Pyridoxamine: the many virtues of a maillard reaction inhibitor. Ann N Y Acad Sci. 2005 Jun;1043:807-16.

Walser, M. et al. Can renal replacement be deferred by a supplemented very low protein diet? J. Am. Soc. Nephrol. 1999 Jan; 10(1): 110-6.

Wanic-Kossowska, M., Bombicki, K., Koziol, L., Czarnecki, R. Levels of L-carnitine in serum of patients with chronic renal failure treated by hemodialysis (HD). Pol. Arch. Med. Wewn. 1998 Apr; 99(4): 314-22.

Wardle, E.N. Antioxidants in the prevention of renal disease. Renal Fail. 1999 Nov; 21(6): 581-91.

Welch, G.N., Loscalzo, J. Homocysteine and atherothrombosis. N. Engl. J. Med. 1998 Apr 9; 338(15): 1042-50.

Wendel, U., Bremer, H.J. Betaine in the treatment of homocystinuria due to 5,10-methylenetetrahydrofolate reductase deficiency. Eur. J. Pediatr. 1984; 142: 147-50.

Wilcken, D.E., Wilcken, B., Dudman, N.P.B., Tyrrell, P.A. Homocystinuria--the effects of betaine in the treatment of patients not responsive to pyridoxine. N. Engl. J. Med. 1983; 309: 448-53.

Williams ME, Bolton WK, Khalifah RG, Degenhardt TP, Schotzinger RJ, McGill JB. Effects of pyridoxamine in combined phase 2 studies of patients with type 1 and type 2 diabetes and overt nephropathy. Am J Nephrol. 2007;27(6):605-14.

Williams ME. New potential agents in treating diabetic kidney disease: the fourth act. Drugs. 2006;66(18):2287-98.

Williams, C.P., Child, D.F., Hudson, P.R., Davies, G.K., Davies, M.G., John, R., Anandaram, P.S., De Bolla, A.R. Why oral calcium supplements may reduce renal stone disease: report of a clinical pilot study. J. Clin. Pathol. 2001 Jan; 54(1): 54-62.

Wojcikowski K, Stevenson L, Leach D, Wohlmuth H, Gobe G. Antioxidant capacity of 55 medicinal herbs traditionally used to treat the urinary system: a comparison using a sequential three-solvent extraction process. J Altern Complement Med. 2007 Jan-Feb;13(1):103-9.

Wratten, M.L. et al. Haemolipodialysis. Blood Purif. 1999; 17(2-3): 127-33.

Yao X, Panichpisal K, Kurtzman N, Nugent K. Cisplatin nephrotoxicity: a review. Am J Med Sci. 2007Aug;334(2):115-24.

Yokozawa, T., Chung, H.Y., He, L.Q., Oura, H. Effectiveness of green tea tannin on rats with chronic renal failure. Biosci. Biotechnol. Biochem. 1996 Jun; 60(6): 1000-5.

Yokozawa, T., Nakagawa, T., Lee, K.I., Cho, E.J., Terasawa, K., Takeuchi, S. Effects of green tea tannin on cisplatin-induced nephropathy in LLC-PK1 cells and rats. J. Pharm. Pharmacol. 1999 Nov; 51(11): 1325-31.

Yuan, C.F., Lin, C.Y., Chen, T.W., Yang, M.L., Ng, H.T. Linkage analysis of families with autosomal dominant polycystic kidney disease by KG8-CA marker. Zhonghua Yi Xue Za Zhi 1997 Sep; 60(3): 125-9.